Instead, the currently ongoing dose expansion phase aims to assess the efficacy of pralsetinib in seven different cohorts, including patients with advanced RET+ NSCLC either as first line or in subsequent lines of treatment. Here, RET is linked to non-small cell lung carcinoma.